Bacterial infections are among the most life-threatening healthcare challenges, accounting for approximately 13.6% of global mortality and affecting 1 in 8 individuals worldwide ( Beyond their pathogenic roles, bacteria are integral to human health, especially in the gut, contributing to immune modulation and digestion ( The human microbiome, especially the gut microbiota, comprises numerous symbiotic bacterial species (e.g., Lactobacillus , Bacillus , Clostridium , Enterococcus , and Ruminococcus ) that collectively represent approximately 90% of the gut flora ( While antibiotics effectively eliminate harmful pathogens, their indiscriminate targeting also affects beneficial bacteria, reducing microbial diversity and increasing the likelihood of antibiotic resistance ( The decreasing efficacy of antibiotics and the limited availability of alternative treatments underscore the urgent need for new classes of antibacterial therapeutics
In this respect, a recent work by Guzik et al
Background: Incretins were discovered after it was observed that administration of an oral glucose load leads to a much greater stimulation of insulin release than a comparable glucose load given intravenously (Hansotia & Drucker, 2005)
Dafr braucht er Cystein, Glycin, Glutamat, Selen, Magnesium, B-Vitamine und eine Leber, die nicht dauerhaft berfordert wird
